Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Dermtech Inc's Business Segments
Dermtech Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 4
Regions Reported
-
Dermtech Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Test Revenue99%
- Contractual Activities4.5%
- Contract Revenue Adhesive Patch Kits3.9%
- Contract Revenue Project Management Fees0.5%
- Contract Revenue R N a Extractions0.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Test Revenue | $ 4 | 99% |
| Contractual Activities | $ 0 | 4.5% |
| Contract Revenue Adhesive Patch Kits | $ 0 | 3.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Dermtech Inc dataset.
Description of Dermtech Inc
Dermtech Inc. is a biotechnology company that specializes in the development and commercialization of innovative non-invasive diagnostic tests for skin cancer and other skin conditions. The company's mission is to transform the way skin diseases are diagnosed and managed by providing accurate and convenient tools that improve patient outcomes and lower healthcare costs.
Dermtech's flagship product is the Pigmented Lesion Assay (PLA), which is a non-invasive genomic test for the early detection of melanoma. Traditional methods of diagnosing melanoma involve invasive skin biopsies, which can be costly, time-consuming, and uncomfortable for patients. The PLA, on the other hand, uses an adhesive patch called Adhesive Skin Collection (ASCP) that is applied to the suspicious skin lesion to collect genomic material. This sample is then sent to Dermtech's CLIA-certified laboratory for analysis using advanced genomics and machine learning algorithms.
The PLA has shown high sensitivity and specificity in accurately diagnosing melanoma, with results available within a few days. This non-invasive approach not only reduces the physical and psychological trauma associated with biopsies but also provides more consistency and accuracy in diagnosing melanoma, which can lead to earlier intervention and improved patient outcomes. Moreover, the PLA has the potential to significantly reduce healthcare costs by eliminating unnecessary biopsies and reducing the number of invasive procedures.
In addition to the PLA, Dermtech has also developed other non-invasive tests for various skin conditions. The Non-Melanoma Skin Cancer Assay (NMSCA) is designed to detect the most common types of non-melanoma skin cancer, such as basal cell carcinoma and squamous cell carcinoma. Like the PLA, the NMSCA uses the ASCP patch to collect genomic material from the skin lesion, enabling accurate and early detection of these conditions.
Dermtech is committed to driving innovation in the field of dermatology and has a robust research and development pipeline. The company is continuously working on expanding its portfolio of non-invasive tests and exploring new applications for its technology. Dermtech also collaborates with leading dermatologists and research institutions to generate clinical evidence supporting the efficacy and accuracy of its tests.
The company's business model primarily focuses on a laboratory-based testing approach, where Dermtech conducts the genomic analysis in its own state-of-the-art laboratory facilities. This allows for centralized testing and consistent, high-quality results. Dermtech also collaborates with healthcare providers and payers to ensure broad access to its tests and reimbursement coverage.
In summary, Dermtech Inc. is a biotechnology company at the forefront of revolutionizing the diagnosis and management of skin diseases. Through its non-invasive genomic tests, the company aims to provide accurate, convenient, and cost-effective solutions that can significantly impact patient outcomes and healthcare practices.
Dermtech's flagship product is the Pigmented Lesion Assay (PLA), which is a non-invasive genomic test for the early detection of melanoma. Traditional methods of diagnosing melanoma involve invasive skin biopsies, which can be costly, time-consuming, and uncomfortable for patients. The PLA, on the other hand, uses an adhesive patch called Adhesive Skin Collection (ASCP) that is applied to the suspicious skin lesion to collect genomic material. This sample is then sent to Dermtech's CLIA-certified laboratory for analysis using advanced genomics and machine learning algorithms.
The PLA has shown high sensitivity and specificity in accurately diagnosing melanoma, with results available within a few days. This non-invasive approach not only reduces the physical and psychological trauma associated with biopsies but also provides more consistency and accuracy in diagnosing melanoma, which can lead to earlier intervention and improved patient outcomes. Moreover, the PLA has the potential to significantly reduce healthcare costs by eliminating unnecessary biopsies and reducing the number of invasive procedures.
In addition to the PLA, Dermtech has also developed other non-invasive tests for various skin conditions. The Non-Melanoma Skin Cancer Assay (NMSCA) is designed to detect the most common types of non-melanoma skin cancer, such as basal cell carcinoma and squamous cell carcinoma. Like the PLA, the NMSCA uses the ASCP patch to collect genomic material from the skin lesion, enabling accurate and early detection of these conditions.
Dermtech is committed to driving innovation in the field of dermatology and has a robust research and development pipeline. The company is continuously working on expanding its portfolio of non-invasive tests and exploring new applications for its technology. Dermtech also collaborates with leading dermatologists and research institutions to generate clinical evidence supporting the efficacy and accuracy of its tests.
The company's business model primarily focuses on a laboratory-based testing approach, where Dermtech conducts the genomic analysis in its own state-of-the-art laboratory facilities. This allows for centralized testing and consistent, high-quality results. Dermtech also collaborates with healthcare providers and payers to ensure broad access to its tests and reimbursement coverage.
In summary, Dermtech Inc. is a biotechnology company at the forefront of revolutionizing the diagnosis and management of skin diseases. Through its non-invasive genomic tests, the company aims to provide accurate, convenient, and cost-effective solutions that can significantly impact patient outcomes and healthcare practices.
DermTech Inc. is a biotechnology company that specializes in molecular dermatology, aiming to improve the diagnosis and treatment of skin diseases, particularly skin cancer. The company predominantly focuses on two key segments: non-invasive testing and genomics, which encompass a range of products and services designed for both healthcare providers and patients.
Segments
1. Diagnostics Segment:
- DermTech primarily positions this segment around skin cancer detection and management, particularly melanoma.
- The flagship product within this segment is the DermTech Melanoma Test (DMT), which is a non-invasive genomic test that helps in the early detection of melanoma.
2. Genomics Segment:
- This segment supports the development and validation of genomic insights related to skin health.
- It focuses on the understanding of gene expression profiles to offer deeper insights into skin conditions.
Products
1. DermTech Melanoma Test (DMT):
- The DMT utilizes adhesive patches that collect skin samples from lesions.
- The samples are analyzed for specific gene expressions associated with melanoma, helping to reduce unnecessary biopsies.
- The test aims to provide timely and accurate information about the likelihood of melanoma, guiding treatment decisions.
2. Epicutaneous Testing System:
- This is a device used to collect skin samples without traditional invasive procedures.
- It enhances patient comfort and compliance, and is particularly relevant for patients with suspicious skin lesions.
3. Value-Added Services:
- DermTech offers services to healthcare providers, including education on the use and interpretation of their tests.
- The company also provides support for reimbursement processes, aiding healthcare professionals in navigating insurance requirements for genetic testing.
Services
1. Clinical Consultation:
- DermTech provides clinical support and consultation for physicians to help interpret test results and integrate the findings into patient management plans.
- This service ensures that healthcare providers can make informed decisions based on the genomic data obtained from their tests.
2. Educational Programs:
- The company runs programs aimed at educating healthcare professionals about the advancements in dermatological genomics and the clinical utility of their tests.
- This includes training on the proper collection and handling of skin samples, as well as guidelines on test interpretation.
3. Research Services:
- DermTech engages in ongoing research initiatives to expand the utility of its genomic tests and validate new markers for various skin conditions.
- They also collaborate with academic and research institutions for studies that enhance understanding of skin diseases.
4. Patient Support Initiatives:
- The company has developed initiatives aimed at assisting patients throughout the testing process, ensuring they are informed and comfortable with the procedure.
- This may include informational resources about skin health, melanoma awareness, and guidance on the next steps post-testing.
Future Prospects
DermTech is actively working on expanding its product offerings and exploring additional applications for its technology beyond melanoma. This could involve the development of tests for other dermatological conditions and expanding their genomic testing capabilities to encompass a broader range of skin diseases.
In summary, DermTech Inc. offers a suite of innovative diagnostic products and services aimed at improving the early detection and management of skin cancer and advancing the field of molecular dermatology. Through its focus on non-invasive testing and genomic insights, DermTech continues to position itself as a leader in skin health innovation.
Segments
1. Diagnostics Segment:
- DermTech primarily positions this segment around skin cancer detection and management, particularly melanoma.
- The flagship product within this segment is the DermTech Melanoma Test (DMT), which is a non-invasive genomic test that helps in the early detection of melanoma.
2. Genomics Segment:
- This segment supports the development and validation of genomic insights related to skin health.
- It focuses on the understanding of gene expression profiles to offer deeper insights into skin conditions.
Products
1. DermTech Melanoma Test (DMT):
- The DMT utilizes adhesive patches that collect skin samples from lesions.
- The samples are analyzed for specific gene expressions associated with melanoma, helping to reduce unnecessary biopsies.
- The test aims to provide timely and accurate information about the likelihood of melanoma, guiding treatment decisions.
2. Epicutaneous Testing System:
- This is a device used to collect skin samples without traditional invasive procedures.
- It enhances patient comfort and compliance, and is particularly relevant for patients with suspicious skin lesions.
3. Value-Added Services:
- DermTech offers services to healthcare providers, including education on the use and interpretation of their tests.
- The company also provides support for reimbursement processes, aiding healthcare professionals in navigating insurance requirements for genetic testing.
Services
1. Clinical Consultation:
- DermTech provides clinical support and consultation for physicians to help interpret test results and integrate the findings into patient management plans.
- This service ensures that healthcare providers can make informed decisions based on the genomic data obtained from their tests.
2. Educational Programs:
- The company runs programs aimed at educating healthcare professionals about the advancements in dermatological genomics and the clinical utility of their tests.
- This includes training on the proper collection and handling of skin samples, as well as guidelines on test interpretation.
3. Research Services:
- DermTech engages in ongoing research initiatives to expand the utility of its genomic tests and validate new markers for various skin conditions.
- They also collaborate with academic and research institutions for studies that enhance understanding of skin diseases.
4. Patient Support Initiatives:
- The company has developed initiatives aimed at assisting patients throughout the testing process, ensuring they are informed and comfortable with the procedure.
- This may include informational resources about skin health, melanoma awareness, and guidance on the next steps post-testing.
Future Prospects
DermTech is actively working on expanding its product offerings and exploring additional applications for its technology beyond melanoma. This could involve the development of tests for other dermatological conditions and expanding their genomic testing capabilities to encompass a broader range of skin diseases.
In summary, DermTech Inc. offers a suite of innovative diagnostic products and services aimed at improving the early detection and management of skin cancer and advancing the field of molecular dermatology. Through its focus on non-invasive testing and genomic insights, DermTech continues to position itself as a leader in skin health innovation.